MN gene and protein
OwnerJan Zavada, Silvia Pastorekova +1inventors
InventorsJan Zavada, Silvia Pastorekova, Jaromir Pastorek
Life of this patent
Estimating the term…
Abstract
Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).
Claims14
1-23. (canceled)
An anti-anti-idiotype antibody to an anti-idiotype antibody to a MN-specific antibody, wherein said anti-idiotype antibody comprises an internal image corresponding to an epitope of MN protein, wherein said MN protein has an amino acid sequence of SEQ ID NO:
- 2 that is encoded by a nucleic acid selected from the group consisting of:
- (a) SEQ ID NO:
- 1;
- and
- (b) polynucleotides that differ from SEQ ID NO:
- 1 due to the degeneracy of the genetic code.
28-29. (canceled)
A method of treating a patient with a preneoplastic and/or neoplastic disease, that is characterized by the abnormal expression of MN protein, by administering to said patient a therapeutically effective amount of an anti-anti-idiotype MN-specific antibody.
Dependencies are inferred from the claim text.